On this page you will find our recommendations sorted by BNF chapter.
Appraisal Reports are available to stakeholders on request.
Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on firstname.lastname@example.org
|Actipatch® for management of localised musculoskeletal pain||Recommendation||Not recommended||22/02/2022|
|Etanercept Biosimilar (Benepali®)||Recommendation||Recommended as a 1st line option||05/04/2016|
|Extracorporeal shockwave therapy for plantar fasciitis (NETAG)||Recommendation||Not recommended||10/07/2012|
|Infliximab biosimilars||Recommendation||Recommended as an option||02/06/2015|
|Infliximab Subcutaneous (Remsima®)||Recommendation||Recommended as an option during Covid-19 Pandemic.||22/02/2022|
|Orthotic functional electrical stimulation (FES) for drop foot of neurological origin (updated)||Recommendation||Recommended if patient fulfils specific criteria||08/09/2015|
|Rituximab (MabThera®) for severe rheumatoid arthritis (non-NICE indications) (NETAG)||Recommendation||Recommends rituximab in combination with methotrexate as first-line biological therapy in cases where there is an absolute contraindication to tumour necrosis factor inhibitor||11/10/2011|
|Rituximab Biosimilars||Recommendation||Approved for use as an option.||06/06/2017|
|Sequential use of TNF inhibitors for the treatment of Psoriatic Arthritis||Recommendation||Recommended as an option||08/09/2015|